1-8 of 8
Baher Krayem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Optical Genome Mapping Reclassifies Patients with Intermediate Risk Acute Myeloid Leukemia

Baher Krayem, Nivin moustafa-Hawash, Avraham Frisch, Christina Srouji, Tsila Zuckerman
Journal: Blood
Blood (2024) 144 (Supplement 1): 1559.
https://doi.org/10.1182/blood-2024-206768
Published: 2024
Journal Articles

The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Amir Tafesh, Dana Yehudai-Ofir, Ofrat Beyar-Katz, Hazim Khatib, Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig
Journal: Blood
Blood (2024) 144 (Supplement 1): 3482.
https://doi.org/10.1182/blood-2024-194308
Published: 2024
Journal Articles

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig, Dana Yehudai-Ofir, Boaz Nachmias, Hazim Khatib, Arnon Haran, Shlomzion Aumann
Journal: Blood
Blood (2024) 144 (Supplement 1): 4269.
https://doi.org/10.1182/blood-2024-204627
Published: 2024
Journal Articles

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Vladimir Vainstein, Arnon Haran, Boaz Nachmias
Journal: Blood
Blood (2023) 142 (Supplement 1): 4212.
https://doi.org/10.1182/blood-2023-179194
Published: 2023
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan -Fludarabine and Busulfan-Fludarabine Conditioning Have Similar Efficacy in Patients ≥65 Years Old or Those with Comorbidities

Israel J. Henig, Ohad Geller, Dana Yehudai-Ofir, Baher Krayem, Avraham Frisch, Hazim Khatib, Tsila Zuckerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2166.
https://doi.org/10.1182/blood-2023-180721
Published: 2023
Journal Articles

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Baher Krayem, Tsila Zuckerman, Avraham Frisch, Ilana Slouzkey, Tehila Azoulay, Michal Karmona, Liran I. Shlush, Nathali Kaushansky, Noa Chapal-Ilani, Shimrit Ringelstein-Harlev
Journal: Blood
Blood (2023) 142 (Supplement 1): 4221.
https://doi.org/10.1182/blood-2023-188592
Published: 2023
Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler
Journal: Blood
Blood (2023) 142 (Supplement 1): 5911.
https://doi.org/10.1182/blood-2023-185488
Published: 2023
Journal Articles

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

Baher Krayem, Avraham Frisch, Nurit Horesh, Ronit Leiba, Tsila Zuckerman, Yishai Ofran
Journal: Blood
Blood (2021) 138 (Supplement 1): 3378.
https://doi.org/10.1182/blood-2021-152532
Published: 2021